- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02183246
Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
July 4, 2014 updated by: Boehringer Ingelheim
A Phase III, Double-Blind, Randomized, Placebo-Controlled Study of Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
Determination of efficacy and safety of porfiromycin versus placebo as an adjuvant to radiotherapy in postoperative head and neck a cancer patients as well as assessment of population pharmacokinetic parameters.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female postoperative radical neck surgery patients with histologically proven Stage III or IV (without distant metastases) epidermoid (squamous cell) carcinoma of the head and neck limited to the following locations as defined by the American Joint Commission (AJC): lip and oral cavity, pharynx, or larynx.
- Postoperative radical patients whose specimen had a) microscopic positive tumor cell margins (< 2mm from surgical margin) or b) extranodal capsular spread (perineural-vascular embolization) or c) two or more positive nodes
- Postoperative radical neck patients must have received Radiotherapy (RT).
- Performance status of ≥ 70 on the Karnofsky Performance Score (KPS) at screening.
- Patients ≥ 18 years of age
- Patients must have provided written informed consent prior to participation in the trial.
- Patients must have demonstrated an educational level and a degree of understanding such that they could communicate effectively with the investigator.
Exclusion Criteria:
- Patients that received any prior chemotherapy including mitomycin-C or porfiromycin.
- Treatment with granulocyte, granulocyte-macrophage stimulating factor (G-CSF, GM-CSF) or Interleukin-11 within 30 days prior to start of RT.
- RT within the treatment field for any malignancy within the past five years.
- Patients who had any gross (visible or palpable) residual disease left after surgery.
Patients who met any of the following clinical laboratory criteria upon screening:
- Granulocyte (neutrophil) count of < 1,500/cubic millimeters (mm3)
- Platelets < 75,000/mm3
- Prothrombin time (PT) and partial thromboplastin time (PTT) > 1.5 times the upper limit of normal (ULN) in seconds.
- Women who were pregnant or nursing.
- Women of childbearing potential who were unwilling to utilise a medically acceptable method of contraception (oral contraceptives, intrauterine devices, diaphragm or subdermal implants eg: Norplant®).
- Other malignancies active within the past five years (other than basal or squamous cell carcinomas of the skin outside the planned radiation portals, or in situ carcinoma of the cervix).
- The presence of more than one primary tumor or presence of distant metastases.
- The presence of any other life-threatening illness, such a severe chronic lung, liver, or heart disease that would be expected to be fatal within five years, regardless of the patient's cancer status.
- Patients who participated in a clinical trial with another investigational drug or treatment 30 days prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Porfiromycin + Radiotherapy
|
|
Placebo Comparator: Placebo + Radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to Disease Progression
Time Frame: week 4 and 8 post treatment, every 8 weeks until end of study
|
week 4 and 8 post treatment, every 8 weeks until end of study
|
Maximum toxicity grades of Adverse Events (AE)
Time Frame: until 42 days after end of treatment
|
until 42 days after end of treatment
|
Time to non-accidental death
Time Frame: week 4 and 8 post treatment, every 8 weeks until end of study
|
week 4 and 8 post treatment, every 8 weeks until end of study
|
Serum porfiromycin concentration-time profile
Time Frame: up to week 7
|
up to week 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Death for any reason
Time Frame: 4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
Loss of local or regional control, distant metastasis or death for any reason
Time Frame: 4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
Loss of local or regional control or distant metastasis
Time Frame: 4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
Loss of local or regional control
Time Frame: 4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
4 weeks post treatment for every 8 weeks through 48 weeks, every 12 weeks until end of study
|
Occurrence of Adverse Events
Time Frame: up to week 16
|
up to week 16
|
Significant changes in laboratory tests
Time Frame: up to week 7
|
up to week 7
|
Changes from baseline in Patients health related Quality of life-Questionnaires
Time Frame: week 1, 5, 7, 4 weeks post treatment, every 12 weeks until end of study
|
week 1, 5, 7, 4 weeks post treatment, every 12 weeks until end of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2000
Primary Completion (Actual)
December 1, 2000
Study Registration Dates
First Submitted
July 4, 2014
First Submitted That Met QC Criteria
July 4, 2014
First Posted (Estimate)
July 8, 2014
Study Record Updates
Last Update Posted (Estimate)
July 8, 2014
Last Update Submitted That Met QC Criteria
July 4, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1164.4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
AZ Sint-Jan AVRecruiting
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Jonsson Comprehensive Cancer CenterWithdrawnHead and Neck CarcinomaUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States